Panbesy Dosage & Drug Information

Concise Prescribing Info Full Prescribing Info Contents Description Action Indications/Uses Dosage/Direction for Use Overdosage Contraindications Special Precautions Use In Pregnancy & Lactation Adverse Reactions Drug Interactions Storage MIMS Class ATC Classification Regulatory Classification Presentation/Packing

Concise Prescribing Info

Contents

Phentermine HCl

Indications/Uses

As an adjunct to treatment of patients w/ moderate to severe obesity.

Click to view Panbesy detailed prescribing information

Dosage/Direction for Use

Adult & childn >12 yr 15 mg daily at breakfast & again at lunchtime if required. Alternatively, 30 mg can be taken at breakfast.

Click to view Panbesy detailed prescribing information

Overdosage

View Panbesy overdosage for action to be taken in the event of an overdose.

Administration

Should be taken with food.

Contraindications

Hypersensitivity to phentermine HCl or sympathomimetic amines. Epilepsy. Advanced arteriosclerosis. Severe HTN. Hyperexcitability. Patients w/ CV disease. Hyperthyroidism. Glaucoma. Patients w/ history of drug abuse. During or 14 days following MAOIs administration. Childn <12 yr.

Click to view Panbesy detailed prescribing information

Special Precautions

May develop tolerance to anorectic effect w/in few wk; discontinue use if tolerance occurs. Patients w/ mild HTN. Concomitant use w/ guanethidine; dietary regimen. Possible drug abuse. Possible blurred vision, dizziness or tiredness; may affect ability to drive & use machinery. Not to be used during pregnancy & lactation. Avoid in childn <12 yr.

Click to view Panbesy detailed prescribing information

Use In Pregnancy & Lactation

Click to view Panbesy detailed prescribing information

Adverse Reactions

Mouth dryness, restlessness, headache, insomnia, irritability, dizziness, tremor.

Click to view Panbesy detailed prescribing information

Drug Interactions

May alter insulin requirements in DM w/ concomitant dietary regimen. May decrease hypotensive effect of guanethidine. Not to be given to patients being treated w/ MAOIs or w/in 14 days of stopping treatment. May produce severe HTN w/ β-blockers & amphetamines. May increase risk of CV effects w/ amphetamines & TCAs. May increase risk of cardiac arrhythmias w/ volatile anaesth.

Click to view Panbesy detailed prescribing information

Storage

View Panbesy storage conditions for details to ensure optimal shelf-life.

Description

View Panbesy description for details of the chemical structure and excipients (inactive components).

Action

View Panbesy mechanism of action for pharmacodynamics and pharmacokinetics details.

MIMS Class

Anti-Obesity Agents

ATC Classification

A08AA01 - phentermine ; Belongs to the class of centrally acting antiobesity products. Used in the treatment of obesity.

Regulatory Classification

POM

Presentation/Packing

Form

Panbesy cap 15 mg

Packing/Price

200's

Form

Panbesy cap 30 mg

Packing/Price

200's

Panbesy

phentermine

Manufacturer:

Eurodrug

Distributor:

Apex Pharma Marketing